The DOI matches its Crossref record; 101 of the 101 references it cites were found in a registry or an index; 5 of the 117 sources its claims cite were checked for support.
The four epidemiological stages in the global evolution of inflammatory bowel disease
Open accessAbstract
Inflammatory bowel disease (IBD) is a global disease; its evolution can be stratified into four epidemiological stages: Emergence, Acceleration in Incidence, Compounding Prevalence and Prevalence Equilibrium. In 2020, developing countries are in the Emergence stage, newly industrialized countries are in the Acceleration in Incidence stage, and Western regions are in the Compounding Prevalence stage. Western regions will eventually transition to the Prevalence Equilibrium stage, in which the accelerating prevalence levels off as the IBD population ages and possibly as a result of an unexpected rise in mortality during the COVID-19 pandemic. Mitigating the global burden of IBD will require concerted efforts in disease prevention and health-care delivery innovations that respond to changing demographics of the global IBD population. In this Perspective, we summarize the global epidemiology of IBD and use these data to stratify disease evolution into four epidemiological stages. The global burden of inflammatory bowel disease (IBD) is evolving. This Perspective summarizes the global epidemiology of IBD and its changing burden of disease, postulating that the disease is evolving into four epidemiological stages: Emergence, Acceleration in Incidence, Compounding Prevalence and Prevalence Equilibrium.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
77 Not checked yet · 56 Own interpretation · 6 No basis given · 2 Partly supported · accuracy not yet measured
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“By contrast, some studies have found that IBD incidence in children38, including IBD of very early onset39, has increased in the Western world over the past two decades.”
§ The four epidemiological stages in the global evolution of inflammatory bowel disease > Stage two: Acceleration in Incidence
What the sources say
- Partly supportedcites [38] Roberts S. E. et al. A systematic review and meta analysis of paediatric inflammatory bowel disease incidence and prevalence across Europe. J. Crohns Colitis https://doi.org/10.1093/ecco-jcc/jjaa037 (2020). sourceExperimental — accuracy not yet measured
Section 3.7 reports increases in paediatric IBD incidence in European studies conducted during the past two decades, and section 4.3 describes the increases as widespread across Europe. The review does not establish an increasing trend across the broader Western world. The separate citation 39, not this source, is attached to the very-early-onset clause. (LLM, conf=0.82)
- Supportedcites [39] Benchimol, E. I. et al. Incidence, outcomes, and health services burden of very early onset inflammatory bowel disease. Gastroenterology 147, 803–813 (2014). source
The Abstract reports that, in an Ontario, Canada cohort, very early onset IBD incidence increased from 1994 through 2009. The Incidence of Pediatric IBD section reports a 7.4% annual increase among children younger than six, supporting the part of the citing sentence attributed to this paper. (LLM, conf=0.92)
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Western regions will eventually transition to the Prevalence Equilibrium stage, in which the accelerating prevalence levels off as the IBD population ages and possibly as a result of an unexpected rise in mortality during the COVID-19 pandemic.”
§ The four epidemiological stages in the global evolution of inflammatory bowel disease > Abstract
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“The high incidence of IBD in Nova Scotia might be methodological in origin because incidence calculations relied on administrative databases using non-validated coding algorithms, which are subject to misclassification biases that might have inflated the incidence45.”
§ The four epidemiological stages in the global evolution of inflammatory bowel disease > Stage two: Acceleration in Incidence
What the sources say
- Not checked yetcites [43] Leddin, D., Tamim, H. & Levy, A. R. Decreasing incidence of inflammatory bowel disease in eastern Canada: a population database study. BMC Gastroenterol. 14, 140 (2014). source
- Not checked yetcites [45] Molodecky, N. A. et al. Challenges associated with identifying the environmental determinants of the inflammatory bowel diseases. Inflamm. Bowel Dis. 17, 1792–1799 (2011). source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“In the Western world, numerous population-based epidemiological studies show that the Acceleration in Incidence of IBD spanned the second half of the twentieth century3.”
§ The four epidemiological stages in the global evolution of inflammatory bowel disease > Stage two: Acceleration in Incidence
What the sources say
- Not checked yetcites [3] Molodecky, N. A. et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 142, 46–54 (2012). source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The first stage in the evolution of IBD — Emergence — occurred in North America and Western Europe following the advent of the industrial revolution.”
§ The four epidemiological stages in the global evolution of inflammatory bowel disease > Stage one: Emergence of IBD
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“The majority of population-based studies evaluating inception cohorts from the 1950s to the 1990s showed steadily increasing incidence for both ulcerative colitis and Crohn’s disease3.”
§ The four epidemiological stages in the global evolution of inflammatory bowel disease > Stage two: Acceleration in Incidence
What the sources say
- Not checked yetcites [3] Molodecky, N. A. et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 142, 46–54 (2012). source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“Instead, the exceedingly high incidence of ulcerative colitis was explained by a genetic shift in a stable, geographically enclosed society in conjunction with unique environmental exposures within the population46.”
§ The four epidemiological stages in the global evolution of inflammatory bowel disease > Stage two: Acceleration in Incidence
What the sources say
- Not checked yetcites [46] Hammer, T. et al. Dietary risk factors for inflammatory bowel diseases in a high-risk population: results from the Faroese IBD study. U. Eur. Gastroenterol. J. 7, 924–932 (2019). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The evolution of IBD occurs within Omran’s Degenerative and Human-Influenced Diseases age and has occurred across three distinct epidemiological stages (Fig. 1): Emergence, Acceleration in Incidence and Compounding Prevalence.”
§ The four epidemiological stages in the global evolution of inflammatory bowel disease > Introduction
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In parallel to the great acceleration in human population, the Western world transitioned to the second epidemiological stage in the evolution of IBD: the (Great) Acceleration in Incidence.”
§ The four epidemiological stages in the global evolution of inflammatory bowel disease > Stage two: Acceleration in Incidence
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“Similarly, a longitudinal cohort study of ulcerative colitis in Olmsted County, MN, USA, showed a rise in incidence from 0.6 per 100,000 (1940–43), to 4.0 per 100,000 (1944–53), 6.4 per 100,000 (1954–63), 9.3 per 100,000 (1964–1973), 10.2 per 100,000 (1980–89 and 1990–99) and to 12.2 per 100,000 (2000–2010)28,32.”
§ The four epidemiological stages in the global evolution of inflammatory bowel disease > Stage two: Acceleration in Incidence
What the sources say
- Not checked yetcites [28] Shivashankar, R., Tremaine, W. J., Harmsen, W. S. & Loftus, E. V. Jr. Incidence and prevalence of Crohn’s disease and ulcerative colitis in Olmsted county, Minnesota from 1970 through 2010. Clin. Gastroenterol. Hepatol. 15, 857–863 (2017). source
- Not checked yetcites [32] Loftus, E. V. Jr. et al. Ulcerative colitis in Olmsted County, Minnesota, 1940–1993: incidence, prevalence, and survival. Gut 46, 336–343 (2000). source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- It may state two separate claims as one. 61
- Probably not a substantial claim. 9
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Initially, the incidence was low and flat (0.27 and 0.09 per 100,000 in 1933 and 1943, respectively), but showed a spike towards the 1980s (0.98 per 100,000 in 1953, 2.4 per 100,000 in 1963, 5.2 per 100,000 in 1973 and 9.1 per 100,000 in 1983). Thereafter, the incidence stabilized (6.0 per 100,000 in 1993 and 7.0 per 100,000 in 2003)29–31.”
§ The four epidemiological stages in the global evolution of inflammatory bowel disease > Stage two: Acceleration in Incidence
What the sources say
- Partly supportedcites [29] Gunesh, S., Thomas, G. A., Williams, G. T., Roberts, A. & Hawthorne, A. B. The incidence of Crohn’s disease in Cardiff over the last 75 years: an update for 1996–2005. Aliment. Pharmacol. Ther. 27, 211–219 (2008). sourceExperimental — accuracy not yet measured
The Introduction and Discussion report a Cardiff peak in the early 1980s, supporting the broad historical pattern. Table 2 gives decade-average rates near 6 and 7 per 100,000 for 1986–1995 and 1996–2005, but does not establish the claimed rates for 1993 and 2003 specifically. The Discussion says incidence continued to rise slowly rather than stabilizing. (LLM, conf=0.86)
- Partly supportedcites [30] Mayberry, J., Rhodes, J. & Hughes, L. E. Incidence of Crohn’s disease in Cardiff between 1934–1977. Gut 20, 602–608 (1979). sourceExperimental — accuracy not yet measured
The Results report a low incidence in the 1930s and a rise through the 1970s, from 0.18 per 100,000 per year in 1931–35 to 4.83 in 1971–75. The study covers only 1934–77, so it cannot support the claimed 1983 spike or stabilization in 1993 and 2003; it also does not establish that incidence was flat in the early decades. (LLM, conf=0.91)
- Partly supportedcites [31] Rose, J. D., Roberts, G. M., Williams, G., Mayberry, J. F. & Rhodes, J. Cardiff Crohn’s disease jubilee: the incidence over 50 years. Gut 29, 346–351 (1988). sourceExperimental — accuracy not yet measured
The Results report low incidence in the 1930s and a rise to 8.3 per 100,000 per year in 1981–1985. The paper does not give the claimed 9.1 figure for 1983, and its data end in 1985, so it cannot support the 1993 and 2003 figures or the subsequent stabilization. (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Partly supported
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“For example, in Canada, 0.51% prevalence of IBD in 2008 represented 169,564 individuals with IBD, whereas 402,853 individuals are predicted to be living with IBD in 2030 — a 238% increase from 2008.”
§ The four epidemiological stages in the global evolution of inflammatory bowel disease > Stage three: Compounding Prevalence
plaincorrelationaln = 169,564- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In 2020, developing countries are in the Emergence stage, newly industrialized countries are in the Acceleration in Incidence stage, and Western regions are in the Compounding Prevalence stage.”
§ The four epidemiological stages in the global evolution of inflammatory bowel disease > Abstract
- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper may give no reason why it holds. It may state two separate claims as one.
- Rests on an assumption: Reported incidence and prevalence values from different countries and regions are comparable enough to be combined into a single global staging framework.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“By combining epidemiological principles with temporal prevalence trends, a fourth stage can be postulated: Prevalence Equilibrium, the countervailing force between the increasing mortality of an ageing IBD population and the incidence of IBD (Fig. 1).”
§ The four epidemiological stages in the global evolution of inflammatory bowel disease > Introduction
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“By the 1950s, ulcerative colitis and Crohn’s disease were established in the Western world, which was then in the process of shifting to the second epidemiological stage in the evolution of IBD.”
§ The four epidemiological stages in the global evolution of inflammatory bowel disease > Stage one: Emergence of IBD
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Since 2000 (that is, the end of the second stage within the Western world), the Coalescing Incidence Ranges of Crohn’s disease and ulcerative colitis were 6–11 per 100,000 and 6–15 per 100,000, respectively (12–26 per 100,000 collectively) in the Western world (Fig. 2).”
§ The four epidemiological stages in the global evolution of inflammatory bowel disease > Stage two: Acceleration in Incidence
What the sources say
- Not checked yetcites [4] Ng, S. C. et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 390, 2769–2778 (2018). source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: Reported incidence and prevalence values from different countries and regions are comparable enough to be combined into a single global staging framework.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This stage is associated with rapidly rising incidence and low prevalence.”
§ The four epidemiological stages in the global evolution of inflammatory bowel disease > Stage two: Acceleration in Incidence
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“The investigators articulated an elegant argument that the increased incidence of IBD in the Faroe Islands is not simply an artefact of improved awareness, diagnosis and data capture44.”
§ The four epidemiological stages in the global evolution of inflammatory bowel disease > Stage two: Acceleration in Incidence
What the sources say
- Not checked yetcites [44] Hammer, T., Nielsen, K. R., Munkholm, P., Burisch, J. & Lynge, E. The Faroese IBD study: incidence of inflammatory bowel diseases across 54 years of population-based data. J. Crohns Colitis. 10, 934–942 (2016). source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“By contrast, recognition of IBD in the first half of the twentieth century in developing countries of the time lagged behind that in the Western world”
- Also stated in: § Stage one: Emergence of IBD · plain
“The emergence of IBD in Asia and Latin America occurred later in the twentieth century.”
§ The four epidemiological stages in the global evolution of inflammatory bowel disease > Stage one: Emergence of IBD
What the sources say
- Not checked yetcites [21] Chopra, R. N. & Ray, P. N. Chronic ulcerative colitis. Ind. Med. Gaz. 74, 65–74 (1939).
- Not checked yetcites [2] Kaplan, G. G. & Ng, S. C. Globalisation of inflammatory bowel disease: perspectives from the evolution of inflammatory bowel disease in the UK and China. Lancet Gastroenterol. Hepatol. 1, 307–316 (2016). source
- Not checked yetcites [22] Jiang, X. L. & Cui, H. F. An analysis of 10218 ulcerative colitis cases in China. World J. Gastroenterol. 8, 158–161 (2002). source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Also stated in: § Stage one: Emergence of IBD · plain
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Inflammatory bowel disease (IBD) is a global disease; its evolution can be stratified into four epidemiological stages: Emergence, Acceleration in Incidence, Compounding Prevalence and Prevalence Equilibrium.”
§ The four epidemiological stages in the global evolution of inflammatory bowel disease > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Whereas the incidence of IBD in the Western world increased in the twentieth century, the incidence began to increase in newly industrialized countries at the turn of the twenty-first century4.”
§ The four epidemiological stages in the global evolution of inflammatory bowel disease > Introduction
What the sources say
- Not checked yetcites [4] Ng, S. C. et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 390, 2769–2778 (2018). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“For Crohn’s disease, the Ceiling Incidence Range is in the range 23.8–29.3 per 100,000 (refs4,40,43), and for ulcerative colitis, it is in the range 23.1–57.9 per 100,000 (refs4,43,44).”
§ The four epidemiological stages in the global evolution of inflammatory bowel disease > Stage two: Acceleration in Incidence
What the sources say
- Not checked yetcites [4] Ng, S. C. et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 390, 2769–2778 (2018). source
- Not checked yetcites [40] Su, H. Y., Gupta, V., Day, A. S. & Gearry, R. B. Rising incidence of inflammatory bowel disease in Canterbury, New Zealand. Inflamm. Bowel Dis. 22, 2238–2244 (2016). source
- Not checked yetcites [43] Leddin, D., Tamim, H. & Levy, A. R. Decreasing incidence of inflammatory bowel disease in eastern Canada: a population database study. BMC Gastroenterol. 14, 140 (2014). source
- Not checked yetcites [44] Hammer, T., Nielsen, K. R., Munkholm, P., Burisch, J. & Lynge, E. The Faroese IBD study: incidence of inflammatory bowel diseases across 54 years of population-based data. J. Crohns Colitis. 10, 934–942 (2016). source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“The journey from a few sporadic cases of inflammatory bowel disease (IBD) to millions of people with IBD is a 250-year path beginning with the industrial revolution1.”
§ The four epidemiological stages in the global evolution of inflammatory bowel disease > Introduction
What the sources say
- Not checked yetcites [1] Kaplan, G. G. The global burden of IBD: from 2015 to 2025. Nat. Rev. Gastroenterol. Hepatol. 12, 720–727 (2015). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“In this milieu, IBD emerged in the Western world, starting as a handful of case studies published at the end of the eighteenth century to taking root as a new affliction of health2.”
§ The four epidemiological stages in the global evolution of inflammatory bowel disease > Stage one: Emergence of IBD
What the sources say
- Not checked yetcites [2] Kaplan, G. G. & Ng, S. C. Globalisation of inflammatory bowel disease: perspectives from the evolution of inflammatory bowel disease in the UK and China. Lancet Gastroenterol. Hepatol. 1, 307–316 (2016). source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“the annual incidence of IBD in Bahrain increased from an average of 3 per 100,000 to 12 per 100,000 during the period 1984–2014, but the total prevalent population remained under 200 persons at 26 per 100,000 (0.026%) (ref.47).”
§ The four epidemiological stages in the global evolution of inflammatory bowel disease > Stage two: Acceleration in Incidence
What the sources say
- Not checked yetcites [47] Abdulla, M. et al. Inflammatory bowel disease in Bahrain: single-center experience. Clin. Exp. Gastroenterol. 10, 133–145 (2017). source
plainn = 200- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Furthermore, incidence continues to increase in certain countries including New Zealand40 and some countries/regions in Europe, such as Spain41 and Denmark42.”
§ The four epidemiological stages in the global evolution of inflammatory bowel disease > Stage two: Acceleration in Incidence
What the sources say
- Not checked yetcites [40] Su, H. Y., Gupta, V., Day, A. S. & Gearry, R. B. Rising incidence of inflammatory bowel disease in Canterbury, New Zealand. Inflamm. Bowel Dis. 22, 2238–2244 (2016). source
- Not checked yetcites [41] Chaaro Benallal, D. et al. Evolution of the incidence of inflammatory bowel disease in Southern Spain. Rev. Esp. Enferm. Dig. 109, 757–760 (2017).
- Not checked yetcites [42] Lophaven, S. N., Lynge, E. & Burisch, J. The incidence of inflammatory bowel disease in Denmark 1980–2013: a nationwide cohort study. Aliment. Pharmacol. Ther. 45, 961–972 (2017). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The Ceiling Incidence Range needs to be interpreted cautiously because outliers can represent unique clinical scenarios or methodological biases that skew the incidence range upwards.”
§ The four epidemiological stages in the global evolution of inflammatory bowel disease > Stage two: Acceleration in Incidence
plainconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“a four-decade analysis of the incidence of IBD in Malaysia showed a slow increase from the 1980s (0.36 per 100,000), to the 1990s (0.48 per 100,000) and to the 2000s (0.63 per 100,000), and then more than doubling to 1.46 per 100,000 in the past decade (2010–2018); however, the prevalence of IBD in Malaysia remained low at 23 per 100,000 (0.023%) in 2018 (ref.48).”
§ The four epidemiological stages in the global evolution of inflammatory bowel disease > Stage two: Acceleration in Incidence
What the sources say
- Not checked yetcites [48] Mokhtar, N. M. et al. A four-decade analysis of the incidence trends, sociodemographic and clinical characteristics of inflammatory bowel disease patients at single tertiary centre, Kuala Lumpur, Malaysia. BMC Public Health 19, 550 (2019). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“In many regions in the Western world, the rapidly increasing incidence of IBD levelled off in the last decades of the twentieth century and, in some regions, reduced at the turn of the twenty-first century.”
§ The four epidemiological stages in the global evolution of inflammatory bowel disease > Stage two: Acceleration in Incidence
What the sources say
- Not checked yetcites [4] Ng, S. C. et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 390, 2769–2778 (2018). source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“in southern Spain, the incidence of IBD increased from 3.5 per 100,000 in 1995–2000 to 14.7 per 100,000 in 2001–2014, which is still lower than most reported incidence values in the Western world, for which the mean incidence for the period 2001–2014 was 1.4 times higher (19.77 per 100,000)41.”
§ The four epidemiological stages in the global evolution of inflammatory bowel disease > Stage two: Acceleration in Incidence
What the sources say
- Not checked yetcites [41] Chaaro Benallal, D. et al. Evolution of the incidence of inflammatory bowel disease in Southern Spain. Rev. Esp. Enferm. Dig. 109, 757–760 (2017).
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“By contrast, the Danish territory of the Faroe Islands had the highest worldwide average annual incidence of IBD at 84.2 per 100,000 in 2011, with a predominance of ulcerative colitis44.”
§ The four epidemiological stages in the global evolution of inflammatory bowel disease > Stage two: Acceleration in Incidence
What the sources say
- Not checked yetcites [44] Hammer, T., Nielsen, K. R., Munkholm, P., Burisch, J. & Lynge, E. The Faroese IBD study: incidence of inflammatory bowel diseases across 54 years of population-based data. J. Crohns Colitis. 10, 934–942 (2016). source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“As most countries in the Western world transitioned into the third stage in the evolution of IBD at the end of the twentieth century, newly industrialized countries in Asia and Latin America entered the second stage: the Acceleration in Incidence.”
§ The four epidemiological stages in the global evolution of inflammatory bowel disease > Stage two: Acceleration in Incidence
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: Reported incidence and prevalence values from different countries and regions are comparable enough to be combined into a single global staging framework.
In the paper
“Moreover, a systematic review of clinical and epidemiological studies on IBD from Latin America documented the emergence of IBD in the twentieth century with a rapidly rising incidence during the twenty-first century49.”
§ The four epidemiological stages in the global evolution of inflammatory bowel disease > Stage two: Acceleration in Incidence
What the sources say
- Not checked yetcites [49] Kotze, P. G. et al. Progression of inflammatory bowel diseases throughout Latin America and the Caribbean: a systematic review. Clin. Gastroenterol. Hepatol. 18, 304–312 (2020). source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“In 2008, the calculated prevalence of IBD in Canada and Scotland was 0.51%70 and 0.57%69, respectively, which was similar to the 0.53% reported in Olmsted County in 2011 (ref.28).”
§ The four epidemiological stages in the global evolution of inflammatory bowel disease > Stage three: Compounding Prevalence
What the sources say
- Not checked yetcites [70] Coward S. Forecasting the Future: A Trek through the Changing Landscape of Inflammatory Bowel Disease. Thesis, Univ. Calgary (2019).
- Not checked yetcites [69] Jones, G. R. et al. IBD prevalence in Lothian, Scotland, derived by capture-recapture methodology. Gut 68, 1953–1960 (2019). source
- Not checked yetcites [28] Shivashankar, R., Tremaine, W. J., Harmsen, W. S. & Loftus, E. V. Jr. Incidence and prevalence of Crohn’s disease and ulcerative colitis in Olmsted county, Minnesota from 1970 through 2010. Clin. Gastroenterol. Hepatol. 15, 857–863 (2017). source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Collectively, these factors reveal the incidence of IBD and, over time, the reported incidence steadily increases.”
§ The four epidemiological stages in the global evolution of inflammatory bowel disease > Stage two: Acceleration in Incidence
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“In 2011, the prevalence of IBD was 533 per 100,000 in Olmsted County, and therefore almost doubled again in the 20 years from 1991 (ref.28).”
§ The four epidemiological stages in the global evolution of inflammatory bowel disease > Stage three: Compounding Prevalence
What the sources say
- Not checked yetcites [28] Shivashankar, R., Tremaine, W. J., Harmsen, W. S. & Loftus, E. V. Jr. Incidence and prevalence of Crohn’s disease and ulcerative colitis in Olmsted county, Minnesota from 1970 through 2010. Clin. Gastroenterol. Hepatol. 15, 857–863 (2017). source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Without a cure, and owing to relatively low mortality, patients with IBD diagnosed at a young age can live a long life63.”
§ The four epidemiological stages in the global evolution of inflammatory bowel disease > Stage three: Compounding Prevalence
What the sources say
- Not checked yetcites [63] Bitton, A., Vutcovici, M., Sewitch, M., Suissa, S. & Brassard, P. Mortality trends in Crohn’s disease and ulcerative colitis: a population-based study in Quebec, Canada. Inflamm. Bowel Dis. 22, 416–423 (2016). source
plainconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Moreover, life expectancy has increased with advances in public health and innovations in medicine74.”
§ The four epidemiological stages in the global evolution of inflammatory bowel disease > Stage four: Prevalence Equilibrium
What the sources say
- Not checked yetcites [74] Appleby, J. How long can we expect to live? BMJ 346, f331 (2013). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“Population-based epidemiological studies from Canada and Scotland published in 2019 documented the Compounding Prevalence of IBD: during the twenty-first century, prevalence rose by 3% and 4% per year in Canada and Scotland, respectively9,69.”
§ The four epidemiological stages in the global evolution of inflammatory bowel disease > Stage three: Compounding Prevalence
What the sources say
- Not checked yetcites [9] Coward, S. et al. Past and future burden of inflammatory bowel diseases based on modeling of population-based data. Gastroenterology 156, 1345–1353 (2019). source
- Not checked yetcites [69] Jones, G. R. et al. IBD prevalence in Lothian, Scotland, derived by capture-recapture methodology. Gut 68, 1953–1960 (2019). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“In 2030, this generation will be aged 66–84 years, meaning that nearly one in five people living in the Western world will be over the age of 65 years71.”
§ The four epidemiological stages in the global evolution of inflammatory bowel disease > Stage four: Prevalence Equilibrium
What the sources say
- Not checked yetcites [71] Knickman, J. R. & Snell, E. K. The 2030 problem: caring for aging baby boomers. Health Serv. Res. 37, 849–884 (2002). source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“in the state of São Paulo, Brazil, the incidence of IBD was 1.0 per 100,000 during the period 1986–1990 (ref.50) and peaked at 13.3 per 100,000 during the period 2012–2015, but the prevalence remained low at 22.6 per 100,000 (2001–2005)51.”
§ The four epidemiological stages in the global evolution of inflammatory bowel disease > Stage two: Acceleration in Incidence
What the sources say
- Not checked yetcites [50] Victoria, C. R., Sassak, L. Y. & Nunes, H. R. Incidence and prevalence rates of inflammatory bowel diseases, in midwestern of Sao Paulo State, Brazil. Arq. Gastroenterol. 46, 20–25 (2009). source
- Not checked yetcites [51] Gasparini, R. G., Sassaki, L. Y. & Saad-Hossne, R. Inflammatory bowel disease epidemiology in Sao Paulo State, Brazil. Clin. Exp. Gastroenterol. 11, 423–429 (2018). source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Forecasting models indicate that the prevalence doubling point of 1% would occur over 22 years in Canada (2008 to 2030)9 and 20 years in Scotland (2008 to 2028)69.”
§ The four epidemiological stages in the global evolution of inflammatory bowel disease > Stage three: Compounding Prevalence
What the sources say
- Not checked yetcites [9] Coward, S. et al. Past and future burden of inflammatory bowel diseases based on modeling of population-based data. Gastroenterology 156, 1345–1353 (2019). source
- Not checked yetcites [69] Jones, G. R. et al. IBD prevalence in Lothian, Scotland, derived by capture-recapture methodology. Gut 68, 1953–1960 (2019). source
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The Unmasking of Incidence is essentially a diagnostic bias: more new cases of IBD are diagnosed as the ability to detect IBD improves.”
§ The four epidemiological stages in the global evolution of inflammatory bowel disease > Stage two: Acceleration in Incidence
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
In the paper
“the incidence of IBD (2011–2013) was a low 0.43 per 100,000 in the Philippines as compared with 2.98 per 100,000 in Hong Kong53. Furthermore, within nine separate regions in mainland China, the incidence varied from 0.54 per 100,000 in Xi’an to 3.64 per 100,000 in Guangzhou53.”
§ The four epidemiological stages in the global evolution of inflammatory bowel disease > Stage two: Acceleration in Incidence
What the sources say
- Not checked yetcites [53] Ng, S. C. et al. Population density and risk of inflammatory bowel disease: a prospective population-based study in 13 countries or regions in Asia-Pacific. Am. J. Gastroenterol. 114, 107–115 (2019). source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“in Malaysia the ulcerative colitis to Crohn’s disease ratio was 5:1 in the 1980s and fell to 1.7:1 from 2010 to 2018 (ref.48).”
§ The four epidemiological stages in the global evolution of inflammatory bowel disease > Stage two: Acceleration in Incidence
What the sources say
- Not checked yetcites [48] Mokhtar, N. M. et al. A four-decade analysis of the incidence trends, sociodemographic and clinical characteristics of inflammatory bowel disease patients at single tertiary centre, Kuala Lumpur, Malaysia. BMC Public Health 19, 550 (2019). source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Inhabitants in these urban environments have been exposed to westernization of their society including diets containing higher levels of fat and refined sugars and changes in lifestyle behaviours, such as an increase in smoking, less breastfeeding, greater exposure to antibiotics and improved hygiene and sanitation56.”
§ The four epidemiological stages in the global evolution of inflammatory bowel disease > Stage two: Acceleration in Incidence
What the sources say
- Not checked yetcites [56] Ng, S. C. et al. Environmental risk factors in inflammatory bowel disease: a population-based case-control study in Asia-Pacific. Gut 64, 1063–1071 (2015). source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Consequently, estimating average disease duration over the course of a lifetime is not feasible in IBD; that is, the prevalence of IBD cannot be estimated by multiplying incidence by average disease duration.”
§ The four epidemiological stages in the global evolution of inflammatory bowel disease > Stage three: Compounding Prevalence
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the third epidemiological stage, the ‘tug-of-war’ between incidence and mortality greatly favours incidence, and so prevalence increases.”
§ The four epidemiological stages in the global evolution of inflammatory bowel disease > Stage three: Compounding Prevalence
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Historically, IBD typically emerges in a population as cases of ulcerative colitis, eventually followed by cases of Crohn’s disease. Over time, Crohn’s disease becomes more commonly diagnosed as the incidence approximates and, in some cases, surpasses that of ulcerative colitis49.”
§ The four epidemiological stages in the global evolution of inflammatory bowel disease > Stage two: Acceleration in Incidence
What the sources say
- Not checked yetcites [49] Kotze, P. G. et al. Progression of inflammatory bowel diseases throughout Latin America and the Caribbean: a systematic review. Clin. Gastroenterol. Hepatol. 18, 304–312 (2020). source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“The diagnosis of IBD is skewed towards ulcerative colitis in lower income regions with limited technology (for example, access only to sigmoidoscopy); however, as economies improve, so too does health-care infrastructure (for example, access to specialists and colonoscopy), which improves the ability of physicians to accurately diagnose Crohn’s disease49.”
§ The four epidemiological stages in the global evolution of inflammatory bowel disease > Stage two: Acceleration in Incidence
What the sources say
- Not checked yetcites [49] Kotze, P. G. et al. Progression of inflammatory bowel diseases throughout Latin America and the Caribbean: a systematic review. Clin. Gastroenterol. Hepatol. 18, 304–312 (2020). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“During the second half of the twentieth century, incidence rapidly rose in the Western world, but prevalence remained relatively low (that is, second epidemiological stage).”
§ The four epidemiological stages in the global evolution of inflammatory bowel disease > Stage three: Compounding Prevalence
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Although prevalence is anticipated to increase over the next decade, as regions transition to the fourth stage, the steep slope of prevalence will decline, leading to a lengthening of the prevalence doubling time.”
§ The four epidemiological stages in the global evolution of inflammatory bowel disease > Stage four: Prevalence Equilibrium
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The Western world is in the third epidemiological stage (Compounding Prevalence), and is anticipated to cross towards Prevalence Equilibrium within the next 30 years.”
§ The four epidemiological stages in the global evolution of inflammatory bowel disease > Global IBD epidemiology: 2020 to 2050
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“However, IBD can, and does, manifest among individuals from developing countries.”
§ The four epidemiological stages in the global evolution of inflammatory bowel disease > Global IBD epidemiology: 2020 to 2050
What the sources say
- Not checked yetcites [66] Benchimol, E. I. et al. Inflammatory bowel disease in immigrants to Canada and their children: a population-based cohort study. Am. J. Gastroenterol. 110, 553–563 (2015). source
- Not checked yetcites [81] Bar-Gil Shitrit, A. et al. Inflammatory bowel disease: an emergent disease among Ethiopian Jews migrating to Israel. Inflamm. Bowel Dis. 21, 631–635 (2015). source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“By contrast, in South Korea, which began westernizing earlier, the prevalence of IBD was 57.37 per 100,000 in 2009, but had not quite doubled to 95.59 per 100,000 in 2016, suggesting a Prevalence Doubling Period closer to 10 years79.”
§ The four epidemiological stages in the global evolution of inflammatory bowel disease > Stage four: Prevalence Equilibrium
What the sources say
- Not checked yetcites [79] Kwak, M. S. et al. Emerging trends of inflammatory bowel disease in South Korea: a nationwide population-based study. J. Gastroenterol. Hepatol. 34, 1018–1026 (2019). source
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Moreover, Prevalence Equilibrium might result in a decline in prevalence in certain jurisdictions, which would reduce the overall burden of IBD to society.”
§ The four epidemiological stages in the global evolution of inflammatory bowel disease > Global IBD epidemiology: 2020 to 2050
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper may give no reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“If the prevalence of IBD follows a similar trend in regions such as India and China with populations of more than one billion people57,89, Asia alone might have more cases of IBD than the Western world before 2050 (ref.1).”
§ The four epidemiological stages in the global evolution of inflammatory bowel disease > Global IBD epidemiology: 2020 to 2050
What the sources say
- Not checked yetcites [57] Kedia, S. & Ahuja, V. Epidemiology of inflammatory bowel disease in India: the great shift east. Inflamm. Intest. Dis. 2, 102–115 (2017). source
- Not checked yetcites [89] Ye, L., Cao, Q. & Cheng, J. Review of inflammatory bowel disease in China. ScientificWorldJournal 2013, 296470 (2013). source
- Not checked yetcites [1] Kaplan, G. G. The global burden of IBD: from 2015 to 2025. Nat. Rev. Gastroenterol. Hepatol. 12, 720–727 (2015). source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: The epidemiological trajectory of newly industrialized nations will mirror that of the Western world.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Over the next decade, gastroenterologists involved in adult care will contend with an escalation in the number of patients living with IBD while simultaneously managing an ageing population that will have a mixture of complications of longstanding IBD and age-related comorbidities.”
§ The four epidemiological stages in the global evolution of inflammatory bowel disease > Global IBD epidemiology: 2020 to 2050
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This second indicator of the Prevalence Equilibrium will be seen in future studies that will document prevalence not rising by an anticipated 50% within a period of 10–12.5 years.”
§ The four epidemiological stages in the global evolution of inflammatory bowel disease > Stage four: Prevalence Equilibrium
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“As the IBD population ages, their mortality increases and, in conjunction with stable (and even more so with declining) incidence, the steep positive slope indicative of Compounding Prevalence will eventually become more moderate until the point where prevalence levels off, and potentially declines thereafter.”
§ The four epidemiological stages in the global evolution of inflammatory bowel disease > Stage four: Prevalence Equilibrium
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“For example, Japan and South Korea experienced rapid industrialization after World War II and transitioned into the second stage earlier than other countries in Asia55,84.”
§ The four epidemiological stages in the global evolution of inflammatory bowel disease > Global IBD epidemiology: 2020 to 2050
What the sources say
- Not checked yetcites [55] Mak, W. Y., Zhao, M., Ng, S. C. & Burisch, J. The epidemiology of inflammatory bowel disease: East meets west. J. Gastroenterol. Hepatol. 35, 380–389 (2020). source
- Not checked yetcites [84] Ng, W. K., Wong, S. H. & Ng, S. C. Changing epidemiological trends of inflammatory bowel disease in Asia. Intest. Res. 14, 111–119 (2016). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“For example, in Taiwan, IBD prevalence doubled from 4.54 per 100,000 in 2001–2005 to 9.39 per 100,000 in 2006–2010 but was just short of doubling again in 2011–2015, suggesting a roughly 5-year Prevalence Doubling Period78.”
§ The four epidemiological stages in the global evolution of inflammatory bowel disease > Stage four: Prevalence Equilibrium
What the sources say
- Not checked yetcites [78] Yen, H. H. et al. Epidemiological trend in inflammatory bowel disease in Taiwan from 2001 to 2015: a nationwide populationbased study. Intest. Res. 17, 54–62 (2019). source
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Older individuals with IBD will continue to make up a higher proportion of the adult patients attending gastroenterology clinics (that is, with EWAR-IBD exceeding 0.5) and octogenarians with IBD will become more common.”
§ The four epidemiological stages in the global evolution of inflammatory bowel disease > Global IBD epidemiology: 2020 to 2050
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The Western world will transition to Prevalence Equilibrium stage (stabilization of prevalence) owing to the advancing age of the IBD population as denoted by the ratio of the prevalence among older individuals (aged >64 years) to the prevalence among the working-age population (aged 15–64 years).”
§ The four epidemiological stages in the global evolution of inflammatory bowel disease > Conclusions
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Developing countries are currently in the first stage of evolution (Emergence) and can expect to transition to the second stage if their economies advance and their societies westernize.”
§ The four epidemiological stages in the global evolution of inflammatory bowel disease > Global IBD epidemiology: 2020 to 2050
plainconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: Developing countries' economies will grow and their societies will westernize.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“By contrast, newly industrialized countries that are undergoing rapid increases in incidence currently show very short Prevalence Doubling Periods, which extend as the regions get nearer to stage 3.”
§ The four epidemiological stages in the global evolution of inflammatory bowel disease > Stage four: Prevalence Equilibrium
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Most newly industrialized countries are entrenched in the second stage (Acceleration in Incidence), but if these regions follow the epidemiological patterns of the Western world, they are likely to transition into the third stage over the next three decades.”
§ The four epidemiological stages in the global evolution of inflammatory bowel disease > Global IBD epidemiology: 2020 to 2050
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: The epidemiological trajectory of newly industrialized nations will mirror that of the Western world.
In the paper
“Among people over the age of 60 years who were reported in SECURE-IBD, 20% experienced a severe complication of COVID-19, with older age (adjusted OR 1.04, 95% CI 1.01–1.06) and two or more comorbidities (adjusted OR 2.9, 95% CI 1.1–1.78) associated with poor outcomes.”
§ The four epidemiological stages in the global evolution of inflammatory bowel disease > Global IBD epidemiology: 2020 to 2050
What the sources say
- Not checked yetcites [97] Brenner, E. J. et al. Corticosteroids, but not TNF antagonists, are associated with adverse COVID-19 outcomes in patients with inflammatory bowel diseases: results from an international registry. Gastroenterology 159, 481–491 (2020). source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Every region in the world is currently in one of the first three epidemiological stages of IBD evolution and, with time, will transition through all four stages1 (Fig. 4).”
§ The four epidemiological stages in the global evolution of inflammatory bowel disease > Global IBD epidemiology: 2020 to 2050
What the sources say
- Not checked yetcites [1] Kaplan, G. G. The global burden of IBD: from 2015 to 2025. Nat. Rev. Gastroenterol. Hepatol. 12, 720–727 (2015). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A fundamental discovery that leads to a cure for IBD would dramatically decrease its incidence.”
§ The four epidemiological stages in the global evolution of inflammatory bowel disease > Global IBD epidemiology: 2020 to 2050
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Although the Prevalence Equilibrium stage is conjectural, several signs are indicative of its arrival: decline in the slope of prevalence over time; prolongation of the Prevalence Doubling Period; and an elevated ratio of the prevalence of IBD among older individuals to the prevalence among the working-age population (elderly to working-age ratio; EWAR-IBD).”
§ The four epidemiological stages in the global evolution of inflammatory bowel disease > Stage four: Prevalence Equilibrium
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Consequently, individuals with newly diagnosed IBD will continue to add to the prevalent population, which will continue to drive Compounding Prevalence over the next decade, with prevalence forecast to be 1% by 2030 (ref.9).”
§ The four epidemiological stages in the global evolution of inflammatory bowel disease > Stage four: Prevalence Equilibrium
What the sources say
- Not checked yetcites [9] Coward, S. et al. Past and future burden of inflammatory bowel diseases based on modeling of population-based data. Gastroenterology 156, 1345–1353 (2019). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“The ageing IBD population will have reduced life expectancy from age-related comorbidities such as cardiovascular disease and cancer, as well as a small increased risk of death of patients with IBD as compared with age-matched individuals without IBD as controls63,76.”
§ The four epidemiological stages in the global evolution of inflammatory bowel disease > Stage four: Prevalence Equilibrium
What the sources say
- Not checked yetcites [63] Bitton, A., Vutcovici, M., Sewitch, M., Suissa, S. & Brassard, P. Mortality trends in Crohn’s disease and ulcerative colitis: a population-based study in Quebec, Canada. Inflamm. Bowel Dis. 22, 416–423 (2016). source
- Not checked yetcites [76] Bernstein, C. N., Nugent, Z., Targownik, L. E., Singh, H. & Lix, L. M. Predictors and risks for death in a population-based study of persons with IBD in Manitoba. Gut 64, 1403–1411 (2015). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Moreover, after several decades of accelerated incidence, prevalence will begin to climb rapidly as these regions enter the Compounding Prevalence stage, similar to the experience in the Western world at the turn of the twenty-first century.”
§ The four epidemiological stages in the global evolution of inflammatory bowel disease > Global IBD epidemiology: 2020 to 2050
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: The epidemiological trajectory of newly industrialized nations will mirror that of the Western world.
None of the sources cited for this claim have been checked yet.
In the paper
“A nationwide study in Japan demonstrated a prevalence of IBD of 24 per 100,000 in 1991 (ref.85), which increased to 76 per 100,000 in 2003–2005 (ref.86) and to 228.5 per 100,000 in 2014 (ref.87).”
§ The four epidemiological stages in the global evolution of inflammatory bowel disease > Global IBD epidemiology: 2020 to 2050
What the sources say
- Not checked yetcites [85] Morita, N. et al. Incidence and prevalence of inflammatory bowel disease in Japan: nationwide epidemiological survey during the year 1991. J. Gastroenterol. 30 (Suppl. 8), 1–4 (1995).
- Not checked yetcites [86] Asakura, K. et al. Prevalence of ulcerative colitis and Crohn’s disease in Japan. J. Gastroenterol. 44, 659–665 (2009). source
- Not checked yetcites [87] Murakami, Y. et al. Estimated prevalence of ulcerative colitis and Crohn’s disease in Japan in 2014: an analysis of a nationwide survey. J. Gastroenterol. 54, 1070–1077 (2019). source
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Newly industrialized countries in Asia and Latin America that are embedded in the second epidemiological stage are currently (in 2020) experiencing a juxtaposition of rapidly rising incidence with low prevalence.”
§ The four epidemiological stages in the global evolution of inflammatory bowel disease > Global IBD epidemiology: 2020 to 2050
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Similarly, the prevalence of IBD in South Korea was 42 per 100,000 in 2005 (ref.88), 63.8 per 100,000 in 2010 and 92.8 per 100,000 in 2015 (ref.79).”
§ The four epidemiological stages in the global evolution of inflammatory bowel disease > Global IBD epidemiology: 2020 to 2050
What the sources say
- Not checked yetcites [88] Yang, S. K. et al. Epidemiology of inflammatory bowel disease in the Songpa-Kangdong district, Seoul, Korea, 1986–2005: a KASID study. Inflamm. Bowel Dis. 14, 542–549 (2008). source
- Not checked yetcites [79] Kwak, M. S. et al. Emerging trends of inflammatory bowel disease in South Korea: a nationwide population-based study. J. Gastroenterol. Hepatol. 34, 1018–1026 (2019). source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Acceleration in Incidence is driven by the Unmasking of Incidence, in which economic advance improves detection of IBD, and the True Rise of Incidence occurs owing to westernization of society.”
§ The four epidemiological stages in the global evolution of inflammatory bowel disease > Conclusions
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
It may state two separate claims as one.
The paper relies on this without support.
Reported incidence and prevalence values from different countries and regions are comparable enough to be combined into a single global staging framework.
“In 2020, developing countries are in the Emergence stage, newly industrialized countries are in the Acceleration in Incidence stage, and Western regions are in the Compounding Prevalence stage.”
The paper relies on this without support.
The epidemiological trajectory of newly industrialized nations will mirror that of the Western world.
“if these regions follow the epidemiological patterns of the Western world, they are likely to transition into the third stage over the next three decades”
“If newly industrialized countries follow the same epidemiological patterns as the Western world, then, over the next 30 years, these countries should approximate the Coalescing Incidence Range for IBD in the Western world: 12–26 per 100,000.”
The paper relies on this without support.
Developing countries' economies will grow and their societies will westernize.
“if their economies advance and their societies show greater westernization, the incidence of IBD will rise throughout the twenty-first century”
“Developing countries are currently in the first stage of evolution (Emergence) and can expect to transition to the second stage if their economies advance and their societies westernize.”
The paper relies on this without support.
Natural population growth will continue in the Western world.
“Owing to natural population growth over time, including both new births and projected immigration patterns, the doubling of prevalence from 0.5% to 1.0% in some countries/regions, represents a more than 200% rise in the number of individuals with IBD.”
“Accounting for natural population growth and assuming a 1% prevalence in 2030, the number of people living with IBD in the Western world over the next decade could surpass ten million — the most people with IBD ever recorded (Table 1).”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ The four epidemiological stages in the global evolution of inflammatory bowel disease > Stage three: Compounding Prevalence
“In 2008, the calculated prevalence of IBD in Canada and Scotland was 0.51%70 and 0.57%69, respectively”
§ The four epidemiological stages in the global evolution of inflammatory bowel disease > Stage four: Prevalence Equilibrium
“In Canada, the total (all ages) prevalence of IBD rose from 448 per 100,000 in 2002 to 646 per 100,000 in 2008 to 976 per 100,000 in 2018 (ref.9).”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The four epidemiological stages in the global evolution of inflammatory bowel disease > Introduction
“the ratio of the prevalence of inflammatory bowel disease (IBD) among older people to the prevalence among the working-age population”
§ The four epidemiological stages in the global evolution of inflammatory bowel disease > Stage four: Prevalence Equilibrium
“An EWAR-IBD of 0.33 in 2018 means that 33 individuals with IBD were older than 64 years for every 100 individuals with IBD aged 15–64 years in Canada.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“Individuals born between 1944 and 1964 are known as the ‘baby boomer generation’ from the sharp increase in births stemming from the economic prosperity following the end of World War II71. In 2030, this generation will be aged 66–84 years”
§ The four epidemiological stages in the global evolution of inflammatory bowel disease > Stage four: Prevalence Equilibrium
Reported 84 · recomputed 86
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The four epidemiological stages in the global evolution of inflammatory bowel disease > Global IBD epidemiology: 2020 to 2050
“adjusted OR 2.9”
§ The four epidemiological stages in the global evolution of inflammatory bowel disease > Global IBD epidemiology: 2020 to 2050
“95% CI 1.1–1.78”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The four epidemiological stages in the global evolution of inflammatory bowel disease > Stage three: Compounding Prevalence
“In 2011, the prevalence of IBD was 533 per 100,000 in Olmsted County, and therefore almost doubled again in the 20 years from 1991 (ref.28).”
§ The four epidemiological stages in the global evolution of inflammatory bowel disease > Stage three: Compounding Prevalence
“from 145 per 100,000 in 1965 to 362 per 100,000 in 1991”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The four epidemiological stages in the global evolution of inflammatory bowel disease > Stage two: Acceleration in Incidence
“the Coalescing Incidence Ranges of Crohn’s disease and ulcerative colitis were 6–11 per 100,000 and 6–15 per 100,000, respectively”
§ The four epidemiological stages in the global evolution of inflammatory bowel disease > Stage two: Acceleration in Incidence
“for example, 6–11 per 100,000 for ulcerative colitis”
Citations
Cites
A new coronavirus associated with human respiratory disease in China
Wu, F., Zhao, S., Yu, B., Chen, Y.-M., Wang, W., Song, Z.-G., Hu, Y., Tao, Z.-W., Tian, J.-H., Pei, Y.-Y., et al. (2020) · Nature · doi:10.1038/s41586-020-2008-3 · Cited by 11,688
Darwin, C. R., Darwin, C. R., & Edmonds & Remnants (1859) · J. Murray eBooks · doi:10.5962/bhl.title.59991 · Cited by 7,020
Ng, S. C., Shi, H. Y., Hamidi, N., Underwood, F. E., Tang, W., Benchimol, E. I., Panaccione, R., Ghosh, S., Wu, J. C. Y., Chan, F. K. L., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32448-0 · Cited by 6,087
Self-citationDarwin, C. R. (1859) · J. Murray eBooks · doi:10.5962/bhl.title.68064 · Cited by 4,906
Molodecky, N. A., Soon, I. S., Rabi, D. M., Ghali, W. A., Ferris, M., Chernoff, G., Benchimol, E. I., Panaccione, R., Ghosh, S., Barkema, H. W., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2011.10.001 · Cited by 4,833
Self-citationThe Epidemiologic Transition: A Theory of the Epidemiology of Population Change
Omran, A. R. (2005) · Milbank Quarterly · doi:10.1111/j.1468-0009.2005.00398.x · Cited by 3,989
The trajectory of the Anthropocene: The Great Acceleration
Steffen, W., Broadgate, W., Deutsch, L., Gaffney, O., & Ludwig, C. (2015) · The Anthropocene Review · doi:10.1177/2053019614564785 · Cited by 3,935
The Anthropocene: Are Humans Now Overwhelming the Great Forces of Nature
Steffen, W., Crutzen, P. J., & McNeill, J. R. (2007) · AMBIO: A Journal of the Human Environment · doi:10.1579/0044-7447(2007)36[614:taahno]2.0.co;2 · Cited by 3,487
The Epidemiologic Transition: A Theory of the Epidemiology of Population Change
Omran, A. R. (1971) · The Milbank Memorial Fund Quarterly · doi:10.2307/3349375 · Cited by 2,921
The global burden of IBD: from 2015 to 2025
Kaplan, G. G. (2015) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.150 · Cited by 2,639
Self-citation
Research works printed but not linked: 3
- Wilks, S. Morbid appearances in the intestine of Miss Bankes. Lond. Med. Gazette 2, 264 (1859).
- Dalziel, T. K. Chronic interstitial enteritis. Br. Med. J. 2, 1068–1070 (1913).
- Crutzen, P. J. & Stoermer, E. F. Anthropocene. IGBP Glob. Change Newslet. 41, 17–18 (2000).
Cited by
Sorted by citations
Gros, B., & Kaplan, G. G. (2023) · JAMA · doi:10.1001/jama.2023.15389 · Cited by 776
Self-citationDolinger, M. T., Torres, J., & Vermeire, S. (2024) · The Lancet · doi:10.1016/s0140-6736(23)02586-2 · Cited by 646
Wang, R., Li, Z., Liu, S., & Zhang, D. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-065186 · Cited by 612
Kuenzig, M. E., Fung, S. G., Marderfeld, L., Mak, J. W. Y., Kaplan, G. G., Ng, S. C., Wilson, D. C., Cameron, F., Henderson, P., Kotze, P. G., et al. (2022) · Gastroenterology · doi:10.1053/j.gastro.2021.12.282 · Cited by 608
Self-citationZhang, M., Ma, Y., Ye, X., Zhang, N., Pan, L., & Wang, B. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01464-x · Cited by 571
Global evolution of inflammatory bowel disease across epidemiologic stages
Hracs, L., Windsor, J. W., Gorospe, J., Cummings, M., Coward, S., Buie, M. J., Quan, J., Goddard, Q., Caplan, L., Markovinović, A., et al. (2025) · Nature · doi:10.1038/s41586-025-08940-0 · Cited by 533
Self-citationLewis, J. D., Parlett, L. E., Funk, M. L. J., Brensinger, C. M., Pate, V., Wu, Q., Dawwas, G. K., Weiss, A., Constant, B. D., McCauley, M., et al. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.07.003 · Cited by 392
Macrophages in intestinal homeostasis and inflammatory bowel disease
Hegarty, L. M., Jones, G., & Bain, C. C. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00769-0 · Cited by 386
Sahoo, D. K., Heilmann, R. M., Paital, B., Patel, A., Yadav, V. K., Wong, D. M., & Jergens, A. E. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1217165 · Cited by 357
Wnt signaling pathways in biology and disease: mechanisms and therapeutic advances
Chen, X., Chu, Q., Shi, Q., Zeng, Y., Lu, J., & Li, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02142-w · Cited by 347
The emerging role of oxidative stress in inflammatory bowel disease
Muro, P., Zhang, L., Li, S., Zhao, Z., Jin, T., Mao, F., & Mao, Z. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1390351 · Cited by 332
The metabolic nature of inflammatory bowel diseases
Adolph, T. E., Meyer, M., Schwärzler, J., Mayr, L., Grabherr, F., & Tilg, H. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00658-y · Cited by 316
Buie, M. J., Quan, J., Windsor, J. W., Coward, S., Hansen, T. M., King, J. A., Kotze, P. G., Gearry, R. B., Ng, S. C., Mak, J. W. Y., et al. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2022.06.030 · Cited by 303
Self-citationCD4 T-Cell Subsets and the Pathophysiology of Inflammatory Bowel Disease
Gómez-Bris, R., Saéz, Á., Herrero‐Fernández, B., Rius, C., Sánchez-Martinez, H., & González, J. M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032696 · Cited by 265
Macrophage immunometabolism in inflammatory bowel diseases: From pathogenesis to therapy
Pan, X., Zhu, Q., Pan, L., & Sun, J. T. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108176 · Cited by 252
The role of Lactobacillus in inflammatory bowel disease: from actualities to prospects
Li, C.-L., Peng, K., Xiao, S., Long, Y., & Yu, Q. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01666-w · Cited by 231
Burisch, J. M., Zhao, M., Odes, S. H., Cruz, P. P. D., Vermeire, S., Bernstein, C. N., Kaplan, G. G., Ďuricová, D., Greenberg, D., Melberg, H. O., et al. (2023) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(23)00003-1 · Cited by 215
Self-citationWestern diets and chronic diseases
Adolph, T. E., & Tilg, H. (2024) · Nature Medicine · doi:10.1038/s41591-024-03165-6 · Cited by 224
Implications of the changing epidemiology of inflammatory bowel disease in a changing world
Agrawal, M., & Jess, T. (2022) · United European Gastroenterology Journal · doi:10.1002/ueg2.12317 · Cited by 195
Wei, Y., Fan, Y., Ga, Y., Zhang, Y., Han, J.-C., & Hao, Z. (2021) · Phytomedicine · doi:10.1016/j.phymed.2021.153743 · Cited by 186
Guo, J., Wang, F., Hu, Y., Luo, Y., Wei, Y., Xu, K., Zhang, H., Liu, H., Bo, L., Lv, S., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100881 · Cited by 126
Huang, C., Wang, J., Liu, H., Huang, R., Yan, X., Song, M., Tan, G., & Zhi, F. (2022) · BMC Medicine · doi:10.1186/s12916-022-02352-x · Cited by 188
Recent advances in the treatment of IBD: Targets, mechanisms and related therapies
Liu, J., Di, B., & Xu, L. (2023) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2023.07.001 · Cited by 172
Epidemiology of Inflammatory Bowel Disease across the Ages in the Era of Advanced Therapies
Caron, B., Honap, S., & Peyrin‐Biroulet, L. (2024) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjae082 · Cited by 179
Wang, S., Dong, Z., & Wan, X. (2023) · Autoimmunity Reviews · doi:10.1016/j.autrev.2023.103498 · Cited by 167
Zhu, L., Yu, T., Wang, W., Xu, T., Geng, W., Li, N., & Zan, X. (2024) · Advanced Materials · doi:10.1002/adma.202308728 · Cited by 170
The global burden of inflammatory bowel disease: from 2025 to 2045
Kaplan, G. G. (2025) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01097-1 · Cited by 171
Self-citationAkkermansia muciniphila and its outer protein Amuc_1100 regulates tryptophan metabolism in colitis
Gu, Z.-Y., Pei, W., Shen, Y., Wang, L., Zhu, J., Zhang, Y., Fan, S., Wu, Q., Li, L., & Zhang, Z. (2021) · Food & Function · doi:10.1039/d1fo02172a · Cited by 167
Metabolic Influences of Gut Microbiota Dysbiosis on Inflammatory Bowel Disease
Sultan, S., El‐Mowafy, M., Elgaml, A., Ahmed, T. A., Hassan, H., & Mottawea, W. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.715506 · Cited by 170
Zhang, Y., Liu, J., Han, X., Jiang, H., Zhang, L., Hu, J., Shi, L., & Li, J. (2022) · Frontiers in Public Health · doi:10.2139/ssrn.4163709 · Cited by 158
Nutritional regulation of microbiota-derived metabolites: Implications for immunity and inflammation
Arifuzzaman, M., Collins, N., Guo, C., & Artis, D. (2024) · Immunity · doi:10.1016/j.immuni.2023.12.009 · Cited by 159
Faye, A. S., Allin, K. H., Iversen, A. T., Agrawal, M., Faith, J. J., Colombel, J., & Jess, T. (2023) · Gut · doi:10.1136/gutjnl-2022-327845 · Cited by 151
Incidence of Inflammatory Bowel Disease in Urban China: A Nationwide Population-based Study
Xu, L., He, B., Sun, Y., Li, J., Shen, P., Hu, L., Liu, G., Wang, J., Duan, L., Zhan, S., et al. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.08.013 · Cited by 149
Diet fuelling inflammatory bowel diseases: preclinical and clinical concepts
Adolph, T. E., & Zhang, J. (2022) · Gut · doi:10.1136/gutjnl-2021-326575 · Cited by 147
He, Z., Wang, Z., Song, Y., Liu, Y., Kang, L., Xue, F., Wang, T., Fan, X., Li, Z., Wang, S., et al. (2023) · Journal of Medical Internet Research · doi:10.2196/41518 · Cited by 141
A break in mitochondrial endosymbiosis as a basis for inflammatory diseases
Murphy, M. P., & O’Neill, L. A. J. (2024) · Nature · doi:10.1038/s41586-023-06866-z · Cited by 138
Lin, D., Yang, J., Shao, X., Xu, Y., Ma, G., Jiang, Y., Hu, D., Jiang, Y., & Hu, D. (2024) · International Journal of Colorectal Disease · doi:10.1007/s00384-024-04711-x · Cited by 129
Genetic and Epigenetic Etiology of Inflammatory Bowel Disease: An Update
Jarmakiewicz-Czaja, S., Zielińska, M., Sokal-Dembowska, A., & Filip, R. (2022) · Genes · doi:10.3390/genes13122388 · Cited by 128
The epidemiology of inflammatory bowel disease: Clues to pathogenesis?
Borowitz, S. M. (2023) · Frontiers in Pediatrics · doi:10.3389/fped.2022.1103713 · Cited by 120
Díez-Martín, E., Hernández-Suárez, L., Muñoz‐Villafranca, C., Martin–Souto, L., Astigarraga, E., Ramirez‐Garcia, A., & Barreda‐Gómez, G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137062 · Cited by 121
Navigating the complexities of drug development for inflammatory bowel disease
Honap, S., Jairath, V., Danese, S., & Peyrin‐Biroulet, L. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00953-0 · Cited by 123
Agrawal, M., Christensen, H. S., Bøgsted, M., Colombel, J., Jess, T., & Allin, K. H. (2022) · Gastroenterology · doi:10.1053/j.gastro.2022.07.062 · Cited by 114
Inflammation-specific targeted carriers for local drug delivery to inflammatory bowel disease
Kotla, N. G., Singh, R., Baby, B. V., Rasala, S., Rasool, J., Hynes, S. O., Martin, D., Egan, L. J., Vemula, P. K., Jala, V. R., et al. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121364 · Cited by 105
Li, Z.-Y., Lin, L.-H., Liang, H., Li, Y., Zhao, F., Sun, T., Liu, Z., Zhu, J., Gu, F., Xu, J.-N., et al. (2023) · Annals of Medicine · doi:10.1080/07853890.2023.2290213 · Cited by 106
Iacucci, M., Santacroce, G., Majumder, S., Morael, J., Zammarchi, I., Maeda, Y., Ryan, D., Sabatino, A. D., Rescigno, M., Aburto, M. R., et al. (2024) · Gut · doi:10.1136/gutjnl-2023-331579 · Cited by 110
Nutrition in Patients with Inflammatory Bowel Diseases: A Narrative Review
Roncoroni, L., Gori, R., Elli, L., Tontini, G. E., Doneda, L., Norsa, L., Cuomo, M., Lombardo, V., Scricciolo, A., Caprioli, F., et al. (2022) · Nutrients · doi:10.3390/nu14040751 · Cited by 99
Trivedi, P. J., Hirschfield, G. M., Adams, D., & Vierling, J. M. (2024) · Gastroenterology · doi:10.1053/j.gastro.2024.01.049 · Cited by 101
Solitano, V., Bernstein, C. N., Dotan, I., Dignass, A. U., Domilici, R., Dubinsky, M. C., Gearry, R. B., Hart, A. L., Kaplan, G. G., Ma, C., et al. (2025) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01063-x · Cited by 100
Self-citationAging and IBD: A New Challenge for Clinicians and Researchers
Faye, A. S., & Colombel, J. (2021) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izab039 · Cited by 97
Biomarkers in inflammatory bowel disease: a practical guide
Clough, J., Colwill, M., Poullis, A. P., Pollok, R., Patel, K., & Honap, S. (2024) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848241251600 · Cited by 102
Wan, J., Zhou, J., Wang, Z., Liu, D., Zhang, H., Xie, S., & Wu, K. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003542 · Cited by 93
Zheng, T., Hao, H., Liu, Q., Li, J., Yao, Y., Liu, Y., Zhang, T., Zhang, Z., & Yi, H. (2023) · Nutrients · doi:10.3390/nu15224722 · Cited by 92
The emerging epidemic of inflammatory bowel disease in Asia and Iran by 2035: A modeling study
Olfatifar, M., Zali, M. R., Pourhoseingholi, M. A., Balaii, H., Ghavami, S. B., Іванчук, М. А., Іванчук, П. Р., Nazari, S. H., Shahrokh, S., Sabour, S., et al. (2021) · BMC Gastroenterology · doi:10.1186/s12876-021-01745-1 · Cited by 91
Anthocyanins in Chronic Diseases: The Power of Purple
Panchal, S. K., John, O. D., Mathai, M. L., & Brown, L. (2022) · Nutrients · doi:10.3390/nu14102161 · Cited by 94
Integrating multi-omics to unravel host-microbiome interactions in inflammatory bowel disease
Zhang, Y., Thomas, J. P., Korcsmáros, T., & Gul, L. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101738 · Cited by 88
Update on the epidemiology of inflammatory bowel disease in Asia: where are we now?
Park, S. H. (2022) · Intestinal Research · doi:10.5217/ir.2021.00115 · Cited by 86
Probiotics in inflammatory bowel disease: microbial modulation and therapeutic prospects
Vallejos, O. P., Bueno, S. M., & Kalergis, A. M. (2025) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2024.12.005 · Cited by 91
Management of inflammatory bowel diseases in older adults
Singh, S., Boland, B. S., Jess, T., & Moore, A. A. (2023) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(22)00358-2 · Cited by 87
The progression of inorganic nanoparticles and natural products for inflammatory bowel disease
Li, Q., Lin, L., Zhang, C., Zhang, H., Ma, Y., Qian, H., Chen, X., & Wang, X. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-02246-x · Cited by 84
Madhvapathy, S. R., Bury, M. I., Wang, L. W., Ciatti, J. L., Avila, R. O., Huang, Y. Y., Sharma, A. K., & Rogers, J. A. (2024) · Nature Biomedical Engineering · doi:10.1038/s41551-024-01183-w · Cited by 83
Zhou, T., Xu, W., Wang, Q., Jiang, C., Li, H., Chao, Y., Sun, Y., & Lan, A. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1132420 · Cited by 84
Wu, K., Liu, Y.-Y., Shao, S., Song, W., Chen, X.-H., Dong, Y.-T., & Zhang, Y.-M. (2023) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2023.06.003 · Cited by 84
Zhou, J., Bao, J.-C., Liao, X.-Y., Chen, Y., Wang, L., Fan, Y., Xu, Q., Hao, L.-X., Li, K.-J., Liang, M.-X., et al. (2023) · BMC Public Health · doi:10.1186/s12889-023-17431-8 · Cited by 84
Estevinho, M. M., Midya, V., Cohen‐Mekelburg, S., Allin, K. H., Fuméry, M., Pinho, S. S., Colombel, J., & Agrawal, M. (2024) · Gut · doi:10.1136/gutjnl-2024-332523 · Cited by 81
Genistein-Derived ROS-Responsive Nanoparticles Relieve Colitis by Regulating Mucosal Homeostasis
Fan, W., Zhang, S., Wu, Y., Lu, T., Liu, J., Cao, X., Liu, S., Yan, L., Shi, X., Liu, G., et al. (2021) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.1c09215 · Cited by 80
Kim, Y. S., Hurley, E., Park, Y., & Ko, S. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01042-9 · Cited by 79
Trends of inflammatory bowel disease from the Global Burden of Disease Study (1990-2019)
Dharni, K., Singh, A., Sharma, S., Midha, V., Kaur, K., Mahajan, R., Dulai, P. S., & Sood, A. (2023) · Indian Journal of Gastroenterology · doi:10.1007/s12664-023-01430-z · Cited by 77
Park, J., Jeong, G. H., Song, M., Yon, D. K., Lee, S. W., Koyanagi, A., Jacob, L., Kostev, K., Dragioti, E., Raduà, J., et al. (2023) · Digestive and Liver Disease · doi:10.1016/j.dld.2023.04.003 · Cited by 76
Muzammil, M. A., Fariha, F., Patel, T., Sohail, R., Kumar, M., Khan, E. A., Khanam, B., Kumar, S., Khatri, M., Varrassi, G., et al. (2023) · Cureus · doi:10.7759/cureus.41120 · Cited by 76
Differentiating gastrointestinal tuberculosis and Crohn's disease- a comprehensive review
Choudhury, A. R., Dhillon, J., Sekar, A., Gupta, P. C., Singh, H., & Sharma, V. (2023) · BMC Gastroenterology · doi:10.1186/s12876-023-02887-0 · Cited by 75
Wan, F., Wang, M., Zhong, R., Liang, C., Han, H. L., Liu, L., Zhao, Y. M., Lv, H., Hou, F., Yi, B., et al. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.798052 · Cited by 73
Quaresma, A. B., Damião, A. O. M. C., Coy, C. S. R., Magro, D. O., Hino, A. A. F., Valverde, D. A., Panaccione, R., Coward, S. B., Ng, S. C., Kaplan, G. G., et al. (2022) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2022.100298 · Cited by 73
Self-citationWielding the double-edged sword: Redox drug delivery systems for inflammatory bowel disease
Chen, Y., Shui, M., Yuan, Q., Vong, C. T., Yang, Z., Chen, Z., & Wang, S. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.05.007 · Cited by 73
Epidemiology of Pediatric Inflammatory Bowel Disease
Khan, R., Kuenzig, M. E., & Benchimol, E. I. (2023) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2023.05.001 · Cited by 73
Coward, S., Benchimol, E. I., Bernstein, C. N., Aviña-Zubieta, A., Bitton, A., Carroll, M. W., Cui, Y., Hoentjen, F., Hracs, L., Jacobson, K., et al. (2024) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000002687 · Cited by 72
Self-citationRole of Mitophagy in Regulating Intestinal Oxidative Damage
Wen, X., Tang, L., Zhong, R., Liu, L., Chen, L., & Zhang, H. (2023) · Antioxidants · doi:10.3390/antiox12020480 · Cited by 71
Schwarzfischer, M., Niechcial, A., Lee, S. S., Sinnet, B., Wawrzyniak, M., Laimbacher, A., Atrott, K., Manzini, R., Morsy, Y., Häfliger, J., et al. (2021) · NanoImpact · doi:10.1016/j.impact.2021.100374 · Cited by 72
The 2023 Impact of Inflammatory Bowel Disease in Canada: Epidemiology of IBD
Coward, S. B., Benchimol, E. I., Kuenzig, M. E., Windsor, J. W., Bernstein, C. N., Bitton, A., Jones, J., Lee, K., Murthy, S. K., Targownik, L. E., et al. (2023) · Journal of the Canadian Association of Gastroenterology · doi:10.1093/jcag/gwad004 · Cited by 70
Self-citationBruno, A., Dovizio, M., Milillo, C., Aruffo, E., Pesce, M., Gatta, M., Chiacchiaretta, P., Carlo, P. D., & Ballerini, P. (2024) · Cancers · doi:10.3390/cancers16173079 · Cited by 72
Huang, Y., Xu, J., Sun, G., Cheng, X., An, Y., Yao, X., Nie, G., & Zhang, Y. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2024.122822 · Cited by 70
Gandhi, G. R., Mohana, T., Athesh, K., Hillary, V. E., Vasconcelos, A. B. S., de Franca, M. N. F., Montalvão, M. M., Ceasar, S. A., Jothi, G., Sridharan, G., et al. (2023) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2023.09.012 · Cited by 69
Roles of microRNAs in inflammatory bowel disease
Jung, H., Kim, J., Lee, K. H., Tizaoui, K., Terrazzino, S., Cargnin, S., Smith, L., Koyanagi, A., Jacob, L., Han, L., et al. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.59904 · Cited by 73
Kokulnathan, T., Wang, T., Ahmed, F., & Alshahrani, T. M. (2022) · Chemical Engineering Journal · doi:10.1016/j.cej.2022.138884 · Cited by 67
Nanotechnology for inflammatory bowel disease management: Detection, imaging and treatment
Barani, M., Rahdar, A., Sargazi, S., Amiri, M. S., Sharma, P. K., & Bhalla, N. (2021) · Sensing and Bio-Sensing Research · doi:10.1016/j.sbsr.2021.100417 · Cited by 67
Early Diagnosis, Early Stratification, and Early Intervention to Deliver Precision Medicine in IBD
Noor, N. M., Sousa, P., Paul, S., & Roblin, X. (2021) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izab228 · Cited by 66
Zhang, Z., Chen, L., Qian, Z. M., Li, H., Cai, M., Wang, X., McMillin, S. E., Vaughn, M. G., Liu, K., Shao, Z., et al. (2022) · Environment International · doi:10.1016/j.envint.2022.107084 · Cited by 66
Heavy arch: from inflammatory bowel diseases to metabolic disorders
Adolph, T. E., Meyer, M., Jukic, A., & Tilg, H. (2024) · Gut · doi:10.1136/gutjnl-2024-331914 · Cited by 72
Sasson, A. N., Ingram, R. J. M., Zhang, Z., Taylor, L., Ananthakrishnan, A. N., Kaplan, G. G., Ng, S. C., Ghosh, S. K., & Raman, M. (2021) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(21)00097-2 · Cited by 66
Self-citationA nationwide cohort study of the incidence of inflammatory bowel disease in Sweden from 1990 to 2014
Forss, A., Clements, M., Bergman, D., Roelstraete, B., Kaplan, G. G., Myrelid, P., Halfvarson, J., Olén, O., & Ludvigsson, J. F. (2021) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16735 · Cited by 63
Self-citationOxidative Stress and Antioxidant Nanotherapeutic Approaches for Inflammatory Bowel Disease
Liu, P., Li, Y., Wang, R., Ren, F., & Wang, X. (2021) · Biomedicines · doi:10.3390/biomedicines10010085 · Cited by 63
Chen, X., Xiang, X., Xia, W., Li, X., Wang, S., Ye, S., Tian, L., Zhao, L., Ai, F., Shen, Z., et al. (2023) · Journal of Epidemiology and Global Health · doi:10.1007/s44197-023-00145-w · Cited by 62
Chen, Y., Shui, M., Li, H., Guo, M., Yuan, Q., Hao, W., Wang, T., Zhou, H., Chen, Z., & Wang, S. (2025) · Biomaterials · doi:10.1016/j.biomaterials.2025.123163 · Cited by 63
Pan, Y., Ning, Y., Hu, J. Y., Wang, Z., Chen, X., & Zhao, X. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/9416794 · Cited by 59
RetractedDisulfiram with Cu2+ alleviates dextran sulfate sodium-induced ulcerative colitis in mice
Zhou, W., Zhang, H., Huang, L., Sun, C., Yue, Y., Cao, X., Jia, H.-L., Wang, C., & Gao, Y. (2023) · Theranostics · doi:10.7150/thno.81571 · Cited by 58
Nanoparticle-Based Drug Delivery Systems for Inflammatory Bowel Disease Treatment
Gao, J., Li, J., Luo, Z., Wang, H., & Ma, Z. (2024) · Drug Design Development and Therapy · doi:10.2147/dddt.s461977 · Cited by 59
Yu, Z., Ruan, G., Bai, X., Sun, Y., Yang, H. B., & Jiaming, Q. (2024) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003345 · Cited by 57
Stem Cell Therapy in Inflammatory Bowel Disease: A Review of Achievements and Challenges
Tian, C., Zhang, Y., Yang, M., Xu, H., Zhu, M., Yao, J., Wang, L., Liang, Y., & Li, D. (2023) · Journal of Inflammation Research · doi:10.2147/jir.s400447 · Cited by 56
Wang, F., Yuan, M., Shao, C., Ji, N., Zhang, H., & Li, C. (2023) · Molecules · doi:10.3390/molecules28176182 · Cited by 56
Chen, M., Li, Y., Zhai, Z., Wang, H., Lin, Y., Chang, F., Ge, S., Sun, X., Wei, W., Wang, D., et al. (2025) · Bone Research · doi:10.1038/s41413-024-00381-1 · Cited by 59
Populin, L. C., Stebbing, M. J., & Furness, J. B. (2021) · FASEB BioAdvances · doi:10.1096/fba.2021-00070 · Cited by 55
Metadata
- Authors
- Kaplan, G. G., & Windsor, J. W.
- Affiliations
- University of Calgary (CA)
- Corresponding author
- Kaplan, Gilaad G.
- Venue
- Nature Reviews Gastroenterology & Hepatology
- Published
- 2020-10-08
- Volume
- 18
- Issue
- 1
- Pages
- 56-66
- ISSN
- 1759-5045 (ISSN-L)
- 1759-5053
- PMC
- PMC7542092
- OpenAlex
- W3092547488
- Semantic Scholar
- 33511fa81641766bc09e1a2fe5feb7778a4d4628
- Cited by
- 1,351
- References
- 101
- Citations by year
- 2026: 245 · 2025: 334 · 2024: 298 · 2023: 252 · 2022: 152 · 2021: 70
- FWCI
- 16.93
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Nature Reviews Gastroenterology & Hepatology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes of Health Research (162393_1)
- Topics
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Health Sciences › Medicine › Oncology › Colorectal Cancer Screening and Detection
- Keywords
- inflammatory bowel disease, global epidemiology, disease incidence, prevalence, global burden of disease, COVID-19 mortality, disease prevention, health care delivery, population aging
- MeSH terms
- COVID-19, SARS-CoV-2, Humans, Global Health, Inflammatory Bowel Diseases, Comorbidity, Incidence, Prevalence, Pandemics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
